Press coverage about OncoGenex Pharmaceuticals (NASDAQ:ACHV) has trended positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.1316891673882 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, ValuEngine raised OncoGenex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th.
Shares of OncoGenex Pharmaceuticals (NASDAQ:ACHV) traded up 0.54% on Friday, hitting $2.05. The stock had a trading volume of 16,135 shares. The stock’s market capitalization is $22.44 million. The firm’s 50 day moving average is $2.71 and its 200-day moving average is $3.85. OncoGenex Pharmaceuticals has a one year low of $2.02 and a one year high of $10.18.
OncoGenex Pharmaceuticals (NASDAQ:ACHV) last released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter.
TRADEMARK VIOLATION WARNING: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://transcriptdaily.com/2017/10/08/oncogenex-pharmaceuticals-achv-earns-media-impact-score-of-0-25.html.
OncoGenex Pharmaceuticals Company Profile
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.